VASCULAR ENDOTHELIAL GROWTH factor (VEGF, also designated VEGF-A) is considered to play multiple crucial roles in lung development. Disruption of the VEGF-VEGF receptor (VEGFR) signaling in the developing rat with the aid of the receptor inhibitor Su-5416 not only reduced pulmonary arterial density but also led to impaired alveolarization, emphysema, and pulmonary hypertension (20, 21, 23) . The VEGF null mutation is lethal early in development even in the heterozygous status (13) , but it is possible to obtain development of mice expressing only one of the VEGF isoforms. Mice deleted for the predominant isoforms in the lung exhibited abnormal lung vascular development (25) and respiratory distress at birth (8) . The importance of VEGF for normal lung development is also highlighted by the fact that infants dying from bronchopulmonary dysplasia have reduced pulmonary levels of VEGF (4) .
In the lung, alveolar type II cells are the major source of VEGF (1, 19, 25, 33) , the epithelial cells that secrete surfactant and maintain alveolar epithelial renewal (11) . VEGF production by type II cells is upregulated by hypoxia (27) . The VEGFR-2 [fetal liver kinase-1 (Flk-1)/kinase domain receptor] is expressed early in the lung bud mesenchyme and then in its vascular derivatives (4, 18) ; its expression and that of VEGF show coordinate increase during the course of pre-and postnatal lung development (4) . It has been suggested recently, however, that alveolar type II cells may themselves represent targets for VEGF. Thus human recombinant VEGF was reported to induce type II cell proliferation and to stimulate the expression of surfactant proteins (SP)-A and SP-C in cultured fetal human lung explants (5) . Moreover, mice deficient for the hypoxia-inducible transcription factor (HIF)-2␣ displayed severe respiratory distress at birth due to impaired thinning of alveolar sac septa and defective surfactant production (8) . Importantly, this was overcome by in utero treatment by VEGF (8) . These investigations indicate an involvement of VEGF in the control of alveolar maturation, but raise the question of VEGF effects on type II cells being exerted either directly or indirectly through the release of other mediator(s) from other lung cell type(s). The observations that type II cells express VEGFR-2 (5) and that recombinant VEGF enhanced SP-B and SP-C expression in isolated adult rat lung type II cells, as assessed by semiquantitative RT-PCR (8) , argued in favor of the direct effect. To further analyze the role of VEGF in growth and maturation of the developing lung alveolar epithelial cells, we isolated the latter from the lung of the rat fetus, and we tested the effects of exogenous VEGF on type II cell proliferation and maturation, including production of surfactant phospholipids and proteins. Because VEGF was reported in a transgenic model of overexpression to inhibit type I cell differentiation (37), we also determined whether VEGF influenced the in vitro type II cell-to-type I cell conversion.
MATERIALS AND METHODS
Type II cell isolation and primary culture. Procedures involving animals were in accordance with the rules of the Guide for Care and Use of Laboratory Animals and under the authority of the French Ministry of Agriculture. Dated pregnant Sprague-Dawley rats were purchased from Charles River (Saint-Germain sur l'Arbresle, France). Term is 22 days. On gestational day 20, fetuses were removed through cesarean section under pentobarbital anesthesia of the pregnant rats, and their lungs were collected aseptically. Fetal lung cells were enzymatically dispersed, and type II cells were isolated, as described previously, through serial differential adhesions to plastic and lowspeed centrifugations (7, 17) . Immunolabeling for cytokeratin and vimentin has shown epithelial cells obtained through this procedure to be over 95% pure (17) . Purified type II cells were seeded directly on plastic for proliferation studies (15) and for transdifferentiation into type I cells (9) , or after coating with Engelbreth-Holm-Swarm (EHS) basement membrane matrix to maintain type II cell phenotype (7, 9) in surfactant studies. Cells were allowed to adhere overnight to the substratum under air-CO2 (95%:5% vol/vol) at 37°C in MEM containing 10% FBS. The following morning, FBS-containing medium was removed, cells were rinsed twice with MEM, and a defined culture medium based on DMEM enriched with various additives, including penicillin, streptomycin, bovine transferrin, biotin, sodium selenite, and metal trace elements, was introduced (7, 17) . Cells were incubated for an additional 48 or 72 h under the same conditions; fresh medium was introduced at 48 h for 72-h cultures. Fetal type II cells grown on EHS matrix in this medium have been shown to mature in vitro with accumulation of the various surfactant components (16, 17) and to respond to exogenous growth factors (7) . Media, serum, and antibiotics were from Invitrogen (Cergy-Pontoise, France); additives were from Invitrogen or Sigma (L'Isle d'Abeau, France) and were cell-culture tested. Recombinant human VEGF165 (R&D Systems Europe, Abingdon, UK) and recombinant human keratinocyte growth factor (KGF; R&D Systems Europe) were added to defined culture medium at concentrations specified in RESULTS.
VEGFR-2, CD31, SP-A, SP-B, and T1␣ immunolabeling. Cells grown on EHS matrix were harvested with the aid of Matrisperse (Collaborative Biomedical Products, Bedford, MA) and pelleted. The pellet was immediately frozen on the top of a Tissue-Tek (SakuraEurope, Zoeterwoude, The Netherlands) support. Five-micrometer sections were cut with the aid of a Leica "Jung CM3000" cryostat and fixed in methanol for 5 min at Ϫ20°C. Cells grown on plastic for 48 and 72 h were directly fixed in cold methanol. Sections and cells were rinsed with PBS. For peroxidase-based antibody detection, endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide in PBS before incubation in PBS/1% BSA (PBS/BSA; Sigma) for 30 min to block nonspecific binding sites. After washing, sections were incubated for 1 h with primary antibody, which included a monoclonal antibody against the carboxy terminus of VEGFR-2/Flk-1 (Santa Cruz Biotechnology, Santa Cruz, CA), and a mouse anti-rat CD31 (platelet endothelial cell adhesion molecule-1) monoclonal antibody (BD Biosciences Pharmingen), both diluted 1:50. Sections were washed in PBS-Tween 0.05% and incubated successively with goat anti-mouse biotinylated secondary antibody (Sigma), with extravidin-peroxidase reagent (Sigma) for 30 min, and with diaminobenzidine (Vector Laboratories) for 5 min, and then counterstained with hematoxylin for 30 s. Negative controls were 1) sections incubated with recombinant human VEGF (R&D Systems Europe) to saturate cell receptors before antibody incubation (final concentration: 300 ng/ml), and 2) sections incubated without primary antibody. Sections were viewed with charge-coupled device Iris camera (CCD Iris, Sony) coupled with an optical microscope (Laborlux), and images were obtained with Perfect Image software (ClaraVision, Orsay, France). For immunofluorescent localization, cells were exposed to the blocking solution PBS/BSA before incubation with the primary antibodies, which included the anti-VEGFR-2 antibody, polyclonal rabbit anti-SP-A (gift from M. Post) or anti-SP-B (gift from J. A. Whitsett) antibodies, and a monoclonal antibody against rat alveolar epithelial type I cell surface marker T1␣ (gift from M. C. Williams). After washing, either FITCconjugated goat anti-rabbit or rhodamine-conjugated goat anti-mouse IgG antibodies (all from Biomeda) were used. Double labeling was performed for colocalization of markers. Sections or cells were observed with the aid of a Zeiss Axioskop-40 fluorescence microscope at the appropriate excitation and detection wavelengths. Images were electronically obtained with Kappa ImageBase software.
Western blot analysis. Cells grown on EHS matrix in the presence or absence of VEGF were lysed in 50 mM Tris⅐HCl buffer, pH 7.4, containing 150 mM NaCl, 2 mM EDTA, 5 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 0.3% NP-40, and 0.2% Triton X-100. Lysates were suspended in reducing or nonreducing Laemmli sample buffer, boiled for 5 min, and separated by 6 or 12% SDS-PAGE in Tris-glycine-SDS or Tris-tricine-SDS running buffer. Proteins were transferred onto Immobilon membranes (Millipore, Bedford, MA), blocked with 10% nonfat milk, and probed with anti-VEGFR-2/Flk-1 antibody or rabbit polyclonal anti-SP-B antibody, as specified above, and mouse monoclonal anti-␤ actin antibody (Sigma). Blots were probed with a horseradish peroxidase-conjugated secondary antibody and detected by using Enhanced Chemiluminescence Assay (Perkin Elmer, Courtaboeuf, France).
[ 3 
H]thymidine incorporation and 5-bromo-2Ј-deoxyuridine labeling. [methyl-
3 H]thymidine (1.89 TBq/mmol; Amersham, Orsay, France) was added to defined medium at a final volumic activity of 7.4 kBq/ml (0.2 Ci/ml). After 48-h incorporation by cells cultured on plastic in 24-well culture plates, cells were rinsed twice with cold PBS, and DNA was precipitated with 5% TCA, dissolved in 200 l of 1 N sodium hydroxide, and neutralized by 200 l of 1 N acetic acid (28) . After being scraped with the aid of a rubber policeman, 200-l aliquots were used to determine incorporated radioactivity in OptiPhase "Hisafe" scintillation cocktail (Wallac Scintillation Products, Perkin Elmer). A 5-bromo-2Ј-deoxyuridine (BrdU) labeling kit was purchased from Roche Diagnostics (Mannheim, Germany) and used to label cells cultured on Sonic seal slide wells (Nunc, Naperville, IL); counterstaining of all cell nuclei with dye Hoechst 33258 (Sigma) allowed the proportion of labeled cells to be evaluated. trace amount of [
14 C]dipalmitoylphosphatidylcholine (42 GBq/mmol; Amersham) for determination of recovery, and then sat-PC was separated by osmium-tetroxide treatment and thin-layer chromatography, as described previously (6, 7) . Incorporated activity was counted in OptiScint "Hisafe" scintillation cocktail (Wallac Scintillation Products) by using a double-channel disintegrations per minute program.
Phospholipids of lamellar body fraction. For evaluating the surfactant pool size, cells cultured on EHS matrix in 10-cm petri culture dishes were collected after 48 h for extraction of a subcellular lamellar body fraction through density gradient fractionation (7). Lipids were extracted from the fraction, and aliquot fractions were used for direct determination of total phospholipid (TPL) content or for separation of sat-PC as above; quantification of TPL and sat-PC was performed through phosphate determination in mineralized samples (7) .
RNA isolation, RT-PCR amplification, and Northern analysis. Total RNA was extracted from cultured cells (recovered with Ma- trisperse) and from rat lung and brain, to be used as positive controls by TRIzol reagent (Invitrogen). Purity was checked by the ratio of 260-to 280-nm absorptions. For VEGFR-2 mRNA detection, reverse transcription was performed on 2 g of RNA extracts with AMV Reverse Transcriptase (Promega) for first-strand cDNA synthesis, and PCR amplification was obtained in the presence of specific primer pairs [forward primer: 5Ј-CGATGTCTCCTCCATCGTTT-3Ј; reverse primer: 5Ј-TTCCATCCGGAACAAATCTC-3Ј, as described previously by Maurer et al. (24) ] and Tfl polymerase (Promega) in a protocol of initial denaturation at 94°C for 2 min, 35 cycles of amplification with denaturation at 94°C for 30 s, annealing at 60°C for 1 min, 2 min at 68°C, and final extension for 7 min. Amplification products were visualized by 1% agarose gel electrophoresis. For Northern blot evaluation of the steadystate level of SP transcripts, RNA, 25 g per sample, was fractionated by electrophoresis through 1% agarose/2.2 M formaldehyde gels and blotted onto nylon membranes (Gene Screen, Perkin Elmer). SP-A, SP-B, and SP-C cDNA probes were amplified by RT-PCR from adult rat lung RNA, as described previously (7) . Region 40 -253 of SP-D cDNA was similarly amplified by using sense orientation primer 5Ј-CAACCCTGAGAGTC-CCATAGGTC-3Ј, antisense orientation primer 5Ј-CTCCATGCTTGTC-CTGCTTGTAC-3Ј, and 30 cycles of amplification with an annealing temperature of 52°C for 1 min, extension at 72°C for 1 min, and denaturation at 94°C for 1 min (14) . cDNA probes were purified and labeled with [␣-32 P]dCTP (NEN, Perkin Elmer), as described (7). Conditions for prehybridization, hybridization, and stripping of blots were as described previously (17) . To allow correction for variations in gel loading, the blots were also hybridized with an 18S ribosomal DNA probe. Autoradiograms were obtained from exposure of blots at Ϫ80°C to X-ray films (X-Omat Kodak Scientific Imaging Film, Eastman Kodak, Rochester, NY). Quantification of signal intensity was performed by densitometric analysis of autoradiograms by using the National Institutes of Health Image program.
RESULTS

Detection of VEGFR transcript and protein in type II cells.
Immunoreactive VEGFR-2 have been demonstrated in human fetal lung type II cells (5) . To determine whether these receptors were expressed also in rat type II cells and persisted during culture, they were searched for at the pre-and posttranslational levels. VEGFR-2 transcripts were detected by RT-PCR amplification in cultured cells as in whole lung or brain (Fig. 1A) . Protein analysis by Western blot showed the presence of the receptor in cultured cells independently of the presence of VEGF (Fig. 1B) . Frozen sections of freshly isolated cells or cells cultured for 48 h on EHS matrix in control medium were immunostained for VEGFR-2 antigen. No labeling was obtained from both negative controls (saturation of receptors with VEGF, Fig. 2A, and omission of primary antibody, Fig. 2 , B and C). Positive immunolabeling clearly evidenced the presence of the receptor at the periphery of most of the cultured cells with diaminobenzidine staining (Fig. 2D) , as well as with FITC labeling (Fig. 2E) . Freshly isolated cells were also positively labeled (not shown). The double labeling of cultured cells with anti-VEGFR-2 antibody and either anti-SP-A or anti-SP-B antibody clearly demonstrated that the receptor was actually expressed by cells that all displayed characteristic features of alveolar type II cells (Fig. 3) .
Absence of endothelial cells in type II cell preparations. To determine whether endothelial cells contaminated fetal type II cell preparations, freshly isolated type II cells were labeled with an antibody raised against the endothelial cell marker CD31. No immunostaining was observed, indicating that the preparations were free of endothelial cells (Fig. 4A) , which validates findings from the RT-PCR amplification and Western blot analysis of VEGFR-2 transcripts. The anti-CD31 antibody strongly labeled vessels in whole rat lung sections used as positive control (Fig. 4B) . ]thymidine incorporation into DNA of isolated fetal alveolar type II cells cultured on plastic for 48 h. VEGF did not induce significant change at any of the tested concentrations, whereas 50 ng/ml KGF enhanced incorporation by ϳ4.5 times compared with that in control defined medium containing no growth factor. Values are means Ϯ SE of 8 independent determinations. ***Significantly different from control medium, P Ͻ 0.001. dpm, Disintegrations per minute; prot, protein.
[ 3 H]thymidine incorporation into DNA and BrdU labeling of cultured type II cells.
In a previous study (5), VEGF had been reported to enhance BrdU incorporation into type II cells of human fetal lung explants at concentrations of 50 and 100 ng/ml. In the present study, the effects of VEGF on isolated type II cells were tested through the study of both [ 3 H]thymidine incorporation and BrdU incorporation. The choice of plastic as cell substratum was made because cells cultured on EHS matrix have been reported to grow poorly. Dose-response analysis on [ 3 H] thymidine incorporation by isolated type II cells was tested for VEGF concentrations ranging from 10 to 100 ng/ml. No concentration induced a significant change compared with control conditions (Fig. 5) , whereas 50 ng/ml KGF tested in parallel as positive control increased thymidine incorporation 4.5 times (Fig. 5) . Similarly, no appreciable change in the proportion of BrdU-labeled cells was observed in the presence of VEGF (Fig. 6) . In a total of 500 -600 counted cells for each condition, the proportion of labeled cells was 9.2, 6.3, 9.4, and 7.6% in control condition and in the presence of 25, 50, and 100 ng/ml VEGF, respectively.
[ 3 Fig. 7A, [ 3 H]choline incorporation was significantly increased (ϩ27%) only in the presence of 50 ng/ml VEGF. No significant change was observed either for 25 or 100 ng/ml VEGF. The surfactant pool size estimated by TPL and sat-PC content of subcellular lamellar body fraction extracted from cultured cells was, therefore, determined only in the presence of the VEGF concentration that had increased [ 3 H]choline incorporation, i.e., 50 ng/ml. Significant change was not observed either for TPL or for sat-PC amount of lamellar body fraction in cells cultured in the presence of VEGF (Fig. 7B) , indicating an absence of change in pool size of surfactant phospholipids. 
H]choline incorporation in sat-PC and phospholipid content of lamellar body fraction. As shown in
Steady-state level of SP-A, -B, -C, and -D transcripts.
RNA was extracted from cells cultured on EHS matrix and exposed to 50 or 100 ng/ml VEGF for 48 h. As depicted in Fig. 8A , Northern blotting analysis indicated that VEGF did not change significantly the expression level of SP-A, SP-C, and SP-D transcripts, whatever the concentration. By contrast, SP-B transcript steady-state level was increased fourfold by 100 ng/ml VEGF (P Ͻ 0.001), with 50 ng/ml VEGF being without effect (Fig. 8, A and B) . This increase was not reflected, however, by an increase in the SP-B cell content after 48 h, as assessed by Western blotting (Fig. 8C) .
Effect of VEGF on the in vitro transdifferentiation of alveolar type II into type I cells. Isolated type II cells were maintained for 3 days on plastic, a condition formerly shown to favor their transdifferentiation into type I cells (9) . The cellsurface protein T1␣ was used as a specific marker of type I cells (36) to follow the process of differentiation during the course of culture. T1␣ immunolabeling that was negative in cells at the issue of overnight adhesion to the substratum (Fig.  9A ) appeared during culture (Fig. 9, B and C) . Whereas, in control medium, strong T1␣ immunolabeling was observed with similar intensity at both 48 h (Fig. 9B ) and 72 h (Fig. 9C ) of culture, in the presence of 50 or 100 ng/ml VEGF it was noticeably weaker at 48 h (Fig. 9, D and E) , but not at 72 h (Fig. 9F) . Therefore, although VEGF somewhat delayed the appearance of the marker, it did not prevent cell transdifferentiation, which seemed to be completed at 72 h, despite the continuous presence of VEGF.
DISCUSSION
Previous investigations run in vitro with fetal lung explants or in vivo suggested that alveolar type II cells, which are the major pulmonary source of VEGF, might also represent targets for this growth factor. Our investigation run with primary cultures of isolated type II cells shows much more modest effects of exogenous VEGF, suggestive of indirect action of the latter in previous studies.
Consistent with previous findings in humans (5), we detected immunoreactive VEGFR-2 in type II cells from fetal rat lung, the presence of which persisted during culture. Moreover, we demonstrated the presence of the transcript, which, along with the absence of detection of CD31-positive cells in epithelial cell preparations, argues for actual expression of this receptor in fetal type II cells. Expression of another receptor of VEGF, VEGFR-1 (Flt-1), was also reported in alveolar type II cells in the adult rat (12) , as well as in the human fetus (22) .
Marked increases of epithelium volume density and BrdU uptake by epithelial cells have been shown in fetal lung explants exposed to VEGF, both being suggestive of a role of VEGF as an epithelial cell growth factor (5). In the present experiments, the same recombinant VEGF at the same concentrations failed to induce any increase in thymidine or BrdU incorporation in isolated type II cells, which, by contrast, responded strongly to KGF, consistent with previous findings in adult (26, 35) as well as fetal (7) type II cells. Our findings, therefore, suggest that the proliferative effects of VEGF previously observed in lung explants were indirect. Consistent with the assumption that VEGF does not control alveolar cell proliferation directly is the finding that the VEGFR inhibitor Su-5416 chronically given to rats induced alveolar septal cell apoptosis, but did not inhibit lung cell proliferation (21) .
VEGF increased the rate of [ 3 H]choline incorporation by less than one-third in whole cell sat-PC of isolated type II cells grown on EHS matrix. Comparatively, this effect was much less pronounced than those previously reported for EGF and KGF in the same experimental conditions (7). Moreover, VEGF failed to increase the TPL and sat-PC contents of a lamellar body fraction that were, by contrast, considerably increased by EGF and KGF (7) . Although sat-PC is representative of surfactant, of which it is the most abundant component, it is not exclusive of surfactant but is also present in a lower proportion in other subcellular membrane compartments. The absence of change in lamellar body fraction in VEGFtreated cells suggests that increased choline incorporation may essentially represent stimulation of synthesis of nonsurfactant sat-PC. This appears consistent with the previous finding that VEGF did not enhance choline incorporation in sat-PC in human lung explants, whereas it enhanced it in total PC, which is more representative of nonsurfactant phospholipids (5). Although total PC was found to be reduced in the whole lung of HIF-2 Ϫ/Ϫ mice (8), the surfactant compartment was not explored specifically in this model, and it is not clear whether this was related directly to the observed reduction of VEGF production, or whether the prevention of neonatal respiratory distress observed following intra-amniotic administration of VEGF was linked to an increase in surfactant phospholipids. Reduced glycogen stores after VEGF treatment were interpreted by the authors as an improved maturation of the lung and as the result of a probable utilization for surfactant phospholipid synthesis (8) , because glycogen has been demonstrated to be a precursor of the latter (10) . However, improved morphological maturation of the lung (i.e., thinning of septa) after VEGF treatment evidenced by histological examination However, it appears from both the present and previous (8) findings that VEGF is able to exert a direct stimulating effect on the expression level of the SP-B transcript in isolated type II cells. Despite the extent of this increase at the pretranslational level, we did not detect an increase of SP-B protein content after 48 h of exposure to VEGF. This may be due to the absence of stimulation of SP-B synthesis, to a delay between transcript and protein responses, or to a release of SP-B in the medium.
In addition to surfactant synthesis and secretion, a major function of alveolar type II cells is to serve as precursors of type I cells, the alveolar epithelial cells that perform respiratory gas exchanges (2). Zeng et al. (37) have demonstrated by electron microscopy observation that overexpression of VEGF targeted on the developing pulmonary epithelium in transgenic mice resulted in a lack of type I cell differentiation, whereas the immunostaining for SP-C and Clara cell secretory protein was normal. Hence, in this model, type II cell characteristics Fig. 9 . Effect of VEGF treatment on the in vitro transdifferentiation of alveolar type II cells. Isolated cells were seeded on plastic and cultured for up to 72 h in the presence or absence of 50 and 100 ng/ml VEGF. Transdifferentiation of type II into type I cells was assessed by the appearance during culture of the type I cell marker T1␣ (FITC staining). Each field is representative of 3 experiments. A: absence of staining in epithelial cells after overnight adhesion to plastic (referred to as t0 of culture). B and C: cells cultured in control medium for 48 and 72 h, respectively. T1␣ was strongly expressed at both stages. D and E: cells cultured for 48 h in the presence of 50 and 100 ng/ml VEGF, respectively. T1␣ immunofluorescence was obviously reduced compared with control medium. F: cells cultured for 72 h in the presence of 100 ng/ml VEGF. T1␣ immunofluorescence was similar to that in control medium. VEGF appeared to delay, but not to prevent, the in vitro transdifferentiation of alveolar type II into type I cells. might have remained normal, whereas their differentiation into type I cells was inhibited. To determine whether exogenous VEGF would interfere with the in vitro transformation of type II into type I cells, isolated type II cells were cultured for 72 h on plastic, a condition well established for favoring this transdifferentiation (9) . The appearance of the type I cell marker T1␣ during culture evidenced the in vitro acquisition of type I cell features. T1␣ immunostaining was weaker after 48 h of culture in the presence of VEGF, but this was no longer seen after 72 h. Consistent with previous observations (37), VEGF, therefore, exerted some inhibiting effect on the in vitro transdifferentiation, but this led only to retard, not prevent, the phenomenon. Possibly, the concentration of VEGF in culture medium was insufficient to achieve the preventive effect against type I cell differentiation observed in transgenic mice. This inhibiting effect of VEGF suggests that local VEGF concentration in the developing lung may contribute to orient alveolar epithelial cells toward either type I or type II phenotype.
Finally, our results indicate that, although VEGFRs are present on type II cells, VEGF, at least the isoform that was used herein, does not exert on isolated cells all of the effects that were observed with the same recombinant VEGF in lung explants that contained the other lung cell types. With the exception of a possible role in the control of SP-B expression, a major role of autocrine control mechanisms of type II cell growth and maturation through VEGF signaling is, therefore, questionable. Especially, VEGF does not appear, at least in the rat, to be an autocrine stimulus of type II cell proliferation, contrary to previous assumptions in humans (5) . The apparent discrepancy between our and previous findings may indeed reflect interspecies differences, i.e., VEGF would not have the same effects on rat and human lung cells. Nevertheless, that human recombinant VEGF would have been more efficient in homologous system [human lung explants (5)] but would not have stimulated rat type II cell proliferation because of interspecies differences in responsiveness is unlikely, because 1) it has already been shown previously to exert a variety of biological effects on rat cells (3, 34, 38) and 2) human recombinant VEGF strongly increased rat SP-B transcripts and delayed type I cell differentiation. The functional significance of the presence of VEGFRs on type II cells, therefore, remains poorly defined.
The assumption that autocrine control is not a major mechanism in alveolar cell development is consistent with the paradigm of a requirement for a paracrine control by lung mesenchyme for both growth and differentiation of lung epithelial cells (reviewed in Ref. 29) . Thus distal lung mesenchyme is able to induce growth and branching of the tracheal epithelium and to reorient its differentiation toward an alveolar phenotype (31) . Investigations in mesenchyme-free cultures have evidenced the prominent role of factors of the fibroblast growth factor family, namely FGF-1 and FGF-7 (KGF), in these processes (30) . These paracrine mechanisms that play a crucial role during development (6, 7) appear to be maintained throughout life (32) . A possible interpretation of the previously evidenced effects of VEGF on fetal lung explants (5) or on mouse lung in vivo (8) is a stimulation of mesenchymal and/or endothelial cells by VEGF to produce mediators that would, in turn, exert stimulating effects on alveolar type II cell proliferation and maturation. In conclusion, the present investigation does not bring back into question the crucial importance of VEGF for the development of pulmonary structure, but, as far as growth and maturation of alveolar epithelial cells are concerned, it suggests that VEGF effects are mostly exerted indirectly through reciprocal paracrine interactions involving other cell types.
